| Literature DB >> 35480419 |
Carmina Vejar-Vivar1,2, María Teresa García-Valverde1, Claudia Mardones2, Rafael Lucena1, Soledad Cárdenas1.
Abstract
In-needle microextraction consists of the confinement of the sorbent, by coating or packing, inside a metallic needle. The size of the needles reduces the eluent requirements providing an efficient preconcentration of the analytes. In this work, hypodermic needles coated with polydopamine (PDA) are presented as microextraction devices to isolate six tricyclic antidepressants from oral fluid samples. The coating consists of the in-surface polymerization of dopamine at pH 8.5 and mild conditions (room temperature and water as solvent). The PDA coating over the stainless-steel surface confers the needles with a high extraction ability towards the target analytes. After the extraction, the eluates were analyzed by direct infusion MS spectrometry, working in multiple reaction monitoring (MRM) mode, which provided a sample throughput of 30 samples per hour. The variables affecting the synthesis (number of coating cycles, the concentration of dopamine, and needle surface pre-treatment) and the extraction (sample salinity, sample loading cycles, and the number of elution strokes) were studied in depth. Under the optimum conditions, a matrix-matched calibration model was built. The limits of quantification are between 2 and 5 ng mL-1 with linear ranges up to 1000 ng mL-1 for all analytes. The precision, expressed as relative standard deviation (RSD), is better than 10% for all analytes. Accuracy was calculated as recovery, and the obtained values are between 84% and 107%. A single-blind assay was also performed to evaluate the suitability of the method for real application. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35480419 PMCID: PMC9034363 DOI: 10.1039/d1ra02721b
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Image of the attachment of the PDA-coated hypodermic needle to the micropipette. The Luer connector of the hypodermic needle (a) is connected to the micropipette using a section of a 100 μL plastic tip (b). This device is used for needle conditioning and elution when a lower volume of solutions is required. For sample processing, however, the needle is attached to a 2 mL disposable plastic syringe.
Fig. 2Effect of the PDA-coating cycles on the extraction of the target analytes. The results are presented as the area under the curve (AUC) values once the MRM transition for each analyte is isolated.
Fig. 3Study of the effect of the sample extraction cycles on extraction efficiency.
Fig. 4Calibration curves obtained for each analyte by representing the analyte/IS area ratio against the concentration of the analytes. Each point represents the average of three independent measurements, and error bars illustrate the standard deviation of the corresponding mean value.
Figures of merit of the developed analytical method for the determination of TCAs in oral fluid. Blank oral fluid samples (previously analysed to confirm the absence of the target analytes) were useda
| Analyte | LOD (ng mL−1) | LOQ (ng mL−1) |
| Linear range (ng mL−1) | RSD (%, | Recovery (% | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 6 ng L−1 | 60 ng L−1 | 600 ng L−1 | 6 ng L−1 | 60 ng L−1 | 600 ng L−1 | |||||
| Clomipramine | 1.5 | 5 | 0.9997 | 5–1000 | 2.2 | 2.1 | 4.7 | 95 ± 2 | 99 ± 2 | 92 ± 4 |
| Trimipramine | 1.5 | 5 | 0.9969 | 5–1000 | 7.2 | 6.0 | 7.1 | 101 ± 6 | 87 ± 5 | 95 ± 7 |
| Imipramine | 0.6 | 2 | 0.9983 | 2–1000 | 6.6 | 3.2 | 2.1 | 100 ± 8 | 106 ± 3 | 98 ± 2 |
| Amitriptyline | 1.5 | 5 | 0.9984 | 5–1000 | 9.6 | 2.8 | 2.1 | 96 ± 11 | 94 ± 3 | 95 ± 2 |
| Desipramine | 0.6 | 2 | 0.9966 | 2–1000 | 9.6 | 2.8 | 2.1 | 90 ± 10 | 84 ± 2 | 84 ± 2 |
| Nortriptyline | 1.5 | 5 | 0.9994 | 5–1000 | 3.0 | 4.6 | 3.6 | 92 ± 3 | 107 ± 5 | 96 ± 3 |
LOD, limit of detection; LOQ, limit of quantification; RSD, relative standard deviation.
Comparison of the sensitivity of the proposed method with other counterparts reported for the determination of tricyclic antidepressants in biofluidsa
| Matrix | Sample preparation | Instrumental technique | Analytes | LOD (ng mL−1) | LOQ (ng mL−1) | Linear range | Ref. |
|---|---|---|---|---|---|---|---|
| Oral fluid | PDA coated in-needle microextraction | LC-MS/MS | Clomipramine | 1.5 | 5 | 5–1000 | This paper |
| Trimipramine | 1.5 | 5 | 5–1000 | ||||
| Imipramine | 0.6 | 2 | 2–1000 | ||||
| Amitriptyline | 1.5 | 5 | 5–1000 | ||||
| Desipramine | 0.6 | 2 | 2–1000 | ||||
| Nortriptyline | 1.5 | 5 | 5–1000 | ||||
| Urine | MEPS (PDA-Ag-PPY) | GC-MS | Amitriptyline | 0.03 | 0.10 | 0.03–100 |
|
| Imipramine | 0.05 | 0.20 | 0.05–100 | ||||
| Whole blood | Protein precipitation | LC-QTOF-MS | Amitriptyline | n.a. | 25 | 25–600 |
|
| Clomipramine | 20 | 20–900 | |||||
| Desipramine | 50 | 50–600 | |||||
| Imipramine | 20 | 20–600 | |||||
| Trimipramine | 10 | 10–600 | |||||
| Urine | Poly-(GMA- | LC-UV | Desipramine | 9 | 14 | 14–1000 |
|
| Amitriptyline | 15 | 30 | |||||
| Trimipramine | 15 | 29 | |||||
| Plasma | Cloud-point extraction | LC-MS/MS | Amitriptyline | n.a. | 10 | 10–750 |
|
| Clomipramine | |||||||
| Desipramine | |||||||
| Imipramine | |||||||
| Nortriptyline | |||||||
| Trimipramine | |||||||
| Oral fluid | MEPS (C8/SCX) | UHPLC-TOF-MS | Desipramine | 0.04 | 0.14 | 0.1–10 |
|
| Nortriptyline | 0.01 | 0.03 | |||||
| Imipramine | 0.03 | 0.09 | |||||
| Amitriptyline | 0.02 | 0.08 | |||||
| Oral fluid | SPE (mixed mode Cerex® Trace-B cartridges) | LC-MS/MS | Amitriptyline | — | 10 | 10–1000 |
|
| Clomipramine | |||||||
| Desipramine | |||||||
| Imipramine | |||||||
| Nortriptyline | |||||||
| Trimipramine | |||||||
| Urine | MWCNTs SPE | LC-UV | Desipramine | 40.6 | 135 |
| |
| Imipramine | 50.0 | 166 | |||||
| Nortriptyline | 35.9 | 119 | |||||
| Amitriptyline | 20.1 | 67 | |||||
| Trimipramine | 30.0 | 97 | |||||
| Clomipramine | 18.1 | 59 | |||||
| Plasma | Liquid–liquid extraction | UHPLC-MS/MS | Amitriptyline | 0.2 | 10 | 10–1000 |
|
| Clomipramine | 0.4 | 10 | |||||
| Desipramine | 2.0 | 10 | |||||
| Imipramine | 2.0 | 10 | |||||
| Nortriptyline | 1.0 | 10 | |||||
| Postmortem blood | Salting-out assisted liquid–liquid extraction | UPLC-QTOF-MS | Amitriptyline | 0.010 | 0.05 | 0.05–2 |
|
| Clomipramine | 0.005 | 0.05 | 0.05–2 | ||||
| Desipramine | 0.010 | 0.05 | 0.05–2 | ||||
| Imipramine | 0.005 | 0.05 | 0.05–2 | ||||
| Nortriptyline | 0.010 | 0.05 | 0.05–2 | ||||
| Trimipramine | 0.005 | 0.05 | 0.05–2 | ||||
| Postmortem blood | Mini-QuEChERS | UHPLC-MS/MS | Amitriptyline | 0.0003 | 0.001 | 0.001–0.500 |
|
| Nortriptyline | 0.0003 | 0.001 | 0.001–0.500 | ||||
| Whole blood | Supported liquid extraction | UPLC-MS/MS | Imipramine | 0.0030 | 0.010 | 0.001–200 |
|
| Desipramine | 0.0003 | 0.001 | |||||
| Clomipramine | 0.0003 | 0.001 | |||||
| Amitriptyline | 0.0003 | 0.001 |
PDA-Ag-PPy, polydopamine, silver nanoparticles, and polypyrrole composite; MEPS, microextraction in packed syringe; poly-(GMA-co-EDMA-MWCNTs), poly-(methacrylate-co-ethylene glycol dimethacrylate) containing multiwalled carbon nanotubes; SPE, solid phase extraction; LC, liquid chromatography; UHPLC, ultrahigh pressure liquid chromatography; GC, gas chromatography; MS, mass spectrometry; QTOF, quadrupole time-of-flight; LOD, limit of detection; LOQ, limit of quantification.
Analysis of single-blind samples
| Spiked sample | Identified analyte | Spiked concentration (ng mL−1) | Recovery (%) |
|---|---|---|---|
| 1 | Clomipramine | 100 | 104 ± 7 |
| Amitriptyline | 50 | 89 ± 9 | |
| 2 | Trimipramine | 60 | 97 ± 6 |
| Nortriptyline | 40 | 99 ± 4 | |
| 3 | Imipramine | 250 | 119 ± 8 |
| Desipramine | 150 | 106 ± 5 | |
| 4 | Clomipramine | 50 | 102 ± 2 |
| Imipramine | 370 | 117 ± 12 | |
| Desipramine | 350 | 89 ± 1 | |
| 5 | Trimipramine | 100 | 93 ± 6 |
| Nortriptyline | 80 | 103 ± 1 | |
| 6 | Clomipramine | 500 | 77 ± 1 |
| Amitriptyline | 300 | 96 ± 5 |